(©DSM Jiangshan Pharmaceutical (Jiangsu) Co)
DSM-Firmenich has announced the completion of the sale of its 100% equity interest in DSM Jiangshan Pharmaceutical to Jingjiang Cosfocus Health Technology.
In June 2023, DSM-Firmenich announced a restructuring of its vitamin assets aimed at significant cost reduction. This included closing the Xinghuo vitamin B6 plant in China and shifting to focus solely on vitamin C activities, exclusively on Quali-C from Dalry (UK).
Vitamin C production in Jiangshan ceased completely in mid-May 2023, and the company said it was exploring options for the Jiangshan site, such as partnerships or repurposing manufacturing assets.
Terms of the transaction were not disclosed.
© FoodBev Media Ltd 2024